中等度から重度の化膿性汗腺炎の研究参加者におけるビメキズマブの有効性と安全性を評価する研究 (BE HEARD I)
中等度から重度の化膿性汗腺炎の研究参加者におけるビメキズマブの有効性と安全性を評価する第 3 相無作為化二重盲検プラセボ対照多施設研究
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- Hs0003 50140
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006
- Hs0003 50175
-
-
California
-
Los Angeles、California、アメリカ、90045
- Hs0003 50161
-
San Diego、California、アメリカ、92123
- Hs0003 50220
-
-
Florida
-
North Miami Beach、Florida、アメリカ、33162-4708
- Hs0003 50205
-
Ormond Beach、Florida、アメリカ、32174
- Hs0003 50153
-
Tampa、Florida、アメリカ、33613
- Hs0003 50141
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30309
- Hs0003 50210
-
Watkinsville、Georgia、アメリカ、30677
- Hs0003 50280
-
-
Kentucky
-
Murray、Kentucky、アメリカ、42071
- Hs0003 50425
-
-
Massachusetts
-
Beverly、Massachusetts、アメリカ、01915
- Hs0003 50198
-
Boston、Massachusetts、アメリカ、02215
- Hs0003 50146
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68144
- Hs0003 50194
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89148
- Hs0003 50208
-
-
New Jersey
-
East Windsor、New Jersey、アメリカ、08520
- Hs0003 50137
-
-
New York
-
New York、New York、アメリカ、10003
- Hs0003 50235
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27516
- Hs0003 50151
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- Hs0003 50177
-
Columbus、Ohio、アメリカ、43213
- Hs0003 50138
-
-
Oklahoma
-
Tulsa、Oklahoma、アメリカ、74135
- Hs0003 50204
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- Hs0003 50147
-
-
Rhode Island
-
Johnston、Rhode Island、アメリカ、02919
- Hs0003 50008
-
Providence、Rhode Island、アメリカ、02903
- Hs0003 50180
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37215
- Hs0003 50142
-
-
Texas
-
Arlington、Texas、アメリカ、76011
- Hs0003 50201
-
Dallas、Texas、アメリカ、75246
- Hs0003 50166
-
San Antonio、Texas、アメリカ、78213
- Hs0003 50149
-
-
Washington
-
Seattle、Washington、アメリカ、98101
- Hs0003 50270
-
-
-
-
-
Haifa、イスラエル
- Hs0003 20089
-
Tel Aviv、イスラエル
- Hs0003 20088
-
-
-
-
-
Catania、イタリア
- Hs0003 40261
-
Roma、イタリア
- Hs0003 40257
-
Roma、イタリア
- Hs0003 40263
-
Rozzano、イタリア
- Hs0003 40258
-
Terracina、イタリア
- Hs0003 40331
-
Torino、イタリア
- Hs0003 40330
-
-
-
-
-
Breda、オランダ
- Hs0003 40351
-
Groningen、オランダ
- Hs0003 40292
-
Rotterdam、オランダ
- Hs0003 40264
-
-
-
-
-
Campbelltown、オーストラリア
- Hs0003 30015
-
Carlton、オーストラリア
- Hs0003 30016
-
East Melbourne、オーストラリア
- Hs0003 30011
-
Kogarah、オーストラリア
- Hs0003 30017
-
Woolloongabba、オーストラリア
- Hs0003 30012
-
-
-
-
-
Barrie、カナダ
- Hs0003 50233
-
Richmond Hill、カナダ
- Hs0003 50190
-
Saskatoon、カナダ
- Hs0003 50192
-
St. John's、カナダ
- Hs0003 50173
-
Surrey、カナダ
- Hs0003 50133
-
-
-
-
-
Athens、ギリシャ
- Hs0003 40251
-
Athens、ギリシャ
- Hs0003 40253
-
Thessaloniki、ギリシャ
- Hs0003 40252
-
-
-
-
-
Bern、スイス
- Hs0003 40337
-
Geneva、スイス
- Hs0003 40406
-
-
-
-
-
Badalona、スペイン
- Hs0003 40266
-
Las Palmas de Gran Canaria、スペイン
- Hs0003 40294
-
Pontevedra、スペイン
- Hs0003 40295
-
Seville、スペイン
- Hs0003 40049
-
Valencia、スペイン
- Hs0003 40230
-
-
-
-
-
Aarhus N、デンマーク
- Hs0003 40127
-
-
-
-
-
Ankara、トルコ(Türkiye)
- Hs0003 40053
-
Antalya、トルコ(Türkiye)
- Hs0003 40270
-
Gaziantep、トルコ(Türkiye)
- Hs0003 40273
-
Istanbul、トルコ(Türkiye)
- Hs0003 40050
-
Istanbul、トルコ(Türkiye)
- Hs0003 40272
-
Izmir、トルコ(Türkiye)
- Hs0003 40271
-
-
-
-
-
Berlin、ドイツ
- Hs0003 40325
-
Bochum、ドイツ
- Hs0003 40248
-
Bonn、ドイツ
- Hs0003 40327
-
Darmstadt、ドイツ
- Hs0003 40288
-
Dresden、ドイツ
- Hs0003 40324
-
Kiel、ドイツ
- Hs0003 40249
-
Magdeburg、ドイツ
- Hs0003 40357
-
Mainz、ドイツ
- Hs0003 40174
-
München、ドイツ
- Hs0003 40323
-
Münster、ドイツ
- Hs0003 40177
-
-
-
-
-
Trondheim、ノルウェー
- Hs0003 40332
-
-
-
-
-
Amiens、フランス
- Hs0003 40197
-
Angers、フランス
- Hs0003 40342
-
Le Mans、フランス
- Hs0003 40355
-
Nice、フランス
- Hs0003 40132
-
Rouen、フランス
- Hs0003 40318
-
Saint-Mandé、フランス
- Hs0003 40246
-
Toulon、フランス
- Hs0003 40285
-
-
-
-
-
Brussels、ベルギー
- Hs0003 40004
-
Brussels、ベルギー
- Hs0003 40121
-
Leuven、ベルギー
- Hs0003 40002
-
Liège、ベルギー
- Hs0003 40060
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participant must be at least 18 years of age, at the time of signing the informed consent. If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative
-
Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit
-
Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits
-
Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits
-
Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history
-
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 20 weeks after the last dose of investigational medicinal product (IMP)
Exclusion Criteria:
- Draining tunnel count of >20 at the Baseline Visit
- Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
- Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
- Primary immunosuppressive condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
- Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
- Active infection or history of certain infection(s)
- Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
- Concurrent malignancy. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
- History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
- Known hypersensitivity to any components of bimekizumab or comparative drugs as stated in this protocol
- Concomitant and prior medication restrictions
- Myocardial infarction or stroke within the 6 months prior to the Screening Visit
- Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
- Presence of moderately severe major depression or severe major depression
- Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Bimekizumab dosing regimen 1
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
他の名前:
|
|
実験的:Bimekizumab dosing regimen 2
Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
他の名前:
|
|
実験的:Bimekizumab dosing regimen 3
Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
他の名前:
|
|
プラセボコンパレーター:Placebo Group
Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
他の名前:
Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
時間枠:Week 16
|
HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model. |
Week 16
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
時間枠:Week 16
|
HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model. |
Week 16
|
|
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
時間枠:Baseline, Week 16
|
The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. |
Baseline, Week 16
|
|
Absolute Change From Baseline in Worst Skin Pain Score at Week 16
時間枠:Baseline, Week 16
|
Absolute change from Baseline in Worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model. |
Baseline, Week 16
|
|
Percentage of Participants Achieving Worst Skin Pain Response at Week 16
時間枠:Week 16
|
Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentage of participants shown do not account for model effects using logistic regression model. |
Week 16
|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
時間枠:From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up [SFU] period). |
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
|
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
時間枠:From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). |
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
時間枠:From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:UCB Cares、001 844 599 2273
出版物と役立つリンク
一般刊行物
- Kirby JS, Thorlacius L, Lambert J, Ciaravino V, Rolleri R, Pansar I, Muller E, Pelligra CG, Ingram JR. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL(c)) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. Br J Dermatol. 2025 Jun 20;193(1):93-104. doi: 10.1093/bjd/ljaf067.
- Ingram JR, Lambert J, Ciaravino V, Rolleri R, Pansar I, Peterson L, Pelligra CG, Thorlacius L. Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data. Dermatol Ther (Heidelb). 2025 May;15(5):1093-1111. doi: 10.1007/s13555-025-01346-w. Epub 2025 Mar 28.
- Shi VY, Ingram JR, Lev-Tov H, Schneider-Burrus S, Forman S, Porter ML, Hayama K, Thorlacius L, Lambert J, Vaux T, Lukowski B, Rolleri RL, Szepietowski JC. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Dermatol Ther (Heidelb). 2025 Sep;15(9):2553-2570. doi: 10.1007/s13555-025-01465-4. Epub 2025 Jul 13.
- Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22.
- Ingram JR, Fujita H, Gottlieb AB, Lev-Tov H, Prens E, Sayed CJ, Shi VY, Szepietowski JC, Takahashi K, Frew JW, Lambert J, Davis L, Oh T, Rolleri R, Saintmard MH, Orenstein LAV. Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. Pain Ther. 2025 Dec;14(6):1861-1878. doi: 10.1007/s40122-025-00779-7. Epub 2025 Oct 17.
- Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC. Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II. J Eur Acad Dermatol Venereol. 2026 Feb 14. doi: 10.1111/jdv.70356. Online ahead of print.
- Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. J Am Acad Dermatol. 2026 Mar;94(3):867-878. doi: 10.1016/j.jaad.2025.11.031. Epub 2025 Nov 15.
- Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA. Drugs Real World Outcomes. 2026 Jul 29. doi: 10.1007/s40801-026-00564-8. Online ahead of print.
- Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 2026 Jul 22. doi: 10.1111/jdv.70631. Online ahead of print. No abstract available.
- Daveluy S, Gottlieb AB, Augustin M, Lev-Tov H, Szepietowski JC, Horvath B, Porter ML, Hayama K, Lambert J, Tilt N, Lukowski B, Thorlacius L. Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II. Dermatol Ther (Heidelb). 2026 Jul;16(7):3315-3329. doi: 10.1007/s13555-026-01790-2. Epub 2026 Jun 5.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HS0003
- 2019-002550-23 (EudraCT番号)
- 2019 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 共有時間枠
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 共有アクセス基準
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。